19 Apr 2023 07:00
Director's Dealing
Guildford, UK - 19 April 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 19 April 2023, Dr Miroslav Reljanović, Executive Chairman of Ergomed, transferred 400,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to a former director of the Company. The transfer took place following an exercise of options under an option agreement dated 5 August 2019 between Dr Reljanović and the former director and the exercise price was 1p per ordinary share.
Following the transfer, Dr Reljanović holds 9,129,297 ordinary shares representing 17.98% of the Company's issued share capital.
The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Dr Miroslav Reljanović | |
2 | Reason for the notification | ||
a) | Position/status | Executive Chairman | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Ergomed plc | |
b) | Legal Entity Identifier | 213800BVS8I9VMC1AP84 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1 pence each
GB00BN7ZCY67 | |
b) | Nature of the transaction | Transfer of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
£0.01 | 400,000 | ||
|
| ||
e) | Aggregated information
- Aggregated volume
- Price
- Aggregated total |
400,000
£0.01
£4,000
| |
f) | Date of the transaction | 19 April 2023 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Jonathan Curtain (Chief Financial Officer) Keith Byrne (Senior Vice President, Capital Markets and Strategy) | |
Numis Securities Limited (Nominated Adviser and Joint Broker) | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Euan Brown / Jack McLaren | |
Peel Hunt Securities Limited (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Matthew Neal | ergomed@consilium-comms.com |
About Ergomed plc
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.